The decision to combine therapies should involve discussion with a knowledgeable provider about potential benefits, risks, interactions, and whether monotherapy has been optimized first
1 Key results for oral semaglutide 14 mg: HbA1c reduction: -1.5% (vs -0.1% with placebo) 80% achieved HbA1c below 7.0% (vs 34% with placebo) Weight loss: 2.3-2.6 kg more than placebo Injectable semaglutide: the SUSTAIN programme Across the SUSTAIN trials in type 2 diabetes: Semaglutide 0.5 mg: HbA1c reduction of approximately -1.5%, weight loss of 3-5 kg Semaglutide 1 mg: HbA1c reduction of approximately -1.5% to -1.8%, weight loss of 4.5-6.5 kg What explains the difference
Its important to educate patients about potential side effects and to monitor them closely during treatment
After that, the membranes were incubated with secondary antibodies at room temperature for 2 h against horseradish peroxidase(HRP)-labelled IgG(H + L) (A0208, Beyotime Institute of Technology)
Understanding this side effect, its potential causes, and management strategies helps patients and healthcare professionals optimise treatment whilst maintaining safety and adherence
You may also feel like the effects of the medication arent as strongsuch as noticing your appetite increasing or feeling less full after meals
